Published in Genes Dev on August 15, 2011
MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer (2013) 3.60
MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med (2012) 1.93
The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans. Blood (2012) 1.16
Limiting the power of p53 through the ubiquitin proteasome pathway. Genes Dev (2014) 1.10
MicroRNA-34a modulates MDM4 expression via a target site in the open reading frame. PLoS One (2012) 1.06
Mice engineered for an obligatory Mdm4 exon skipping express higher levels of the Mdm4-S isoform but exhibit increased p53 activity. Oncogene (2014) 0.92
p53 as an intervention target for cancer and aging. Pathobiol Aging Age Relat Dis (2013) 0.89
Mouse models of Mdm2 and Mdm4 and their clinical implications. Chin J Cancer (2013) 0.89
MdmX is required for p53 interaction with and full induction of the Mdm2 promoter after cellular stress. Mol Cell Biol (2012) 0.89
MDMX contains an autoinhibitory sequence element. Proc Natl Acad Sci U S A (2013) 0.89
Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth. J Clin Invest (2015) 0.87
Mdm2 and MdmX as Regulators of Gene Expression. Genes Cancer (2012) 0.87
Targeting p53-MDM2-MDMX loop for cancer therapy. Subcell Biochem (2014) 0.85
Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy. Curr Pharm Des (2013) 0.84
Organocatalytic, diastereo- and enantioselective synthesis of nonsymmetric cis-stilbene diamines: a platform for the preparation of single-enantiomer cis-imidazolines for protein-protein inhibition. J Org Chem (2014) 0.82
Targeting Mdmx to treat breast cancers with wild-type p53. Cell Death Dis (2015) 0.81
Temporal dissection of K-ras(G12D) mutant in vitro and in vivo using a regulatable K-ras(G12D) mouse allele. PLoS One (2012) 0.81
Wild type p53 transcriptionally represses the SALL2 transcription factor under genotoxic stress. PLoS One (2013) 0.79
Pharmacological activation of wild-type p53 in the therapy of leukemia. Exp Hematol (2016) 0.79
Sall2 is required for proapoptotic Noxa expression and genotoxic stress-induced apoptosis by doxorubicin. Cell Death Dis (2015) 0.78
Ribosomal protein S27-like is a physiological regulator of p53 that suppresses genomic instability and tumorigenesis. Elife (2014) 0.77
Chemical Variations on the p53 Reactivation Theme. Pharmaceuticals (Basel) (2016) 0.77
p53 Activity Dominates That of p73 upon Mdm4 Loss in Development and Tumorigenesis. Mol Cancer Res (2015) 0.76
BAC transgenic mice provide evidence that p53 expression is highly regulated in vivo. Cell Death Dis (2015) 0.76
MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation. Oncoscience (2014) 0.76
Targeting RING domains of Mdm2-MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cells. Cell Death Dis (2015) 0.76
MDM2 oligomers: antagonizers of the guardian of the genome. Oncogene (2016) 0.76
Tumorigenesis promotes Mdm4-S overexpression. Oncotarget (2017) 0.75
Targeting MDM4 Splicing in Cancers. Genes (Basel) (2017) 0.75
Reversible modulation of SIRT1 activity in a mouse strain. PLoS One (2017) 0.75
The effect of immunological status, in-vitro treatment and culture time on expression of eleven candidate reference genes in bovine blood mononuclear cells. BMC Immunol (2015) 0.75
The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumorigenesis. J Pathol (2016) 0.75
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell (2005) 24.00
Blinded by the Light: The Growing Complexity of p53. Cell (2009) 17.75
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
Tumor spectrum analysis in p53-mutant mice. Curr Biol (1994) 16.60
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature (1986) 14.56
Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 12.62
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature (1995) 10.18
Modes of p53 regulation. Cell (2009) 9.31
Modeling the therapeutic efficacy of p53 restoration in tumors. Cell (2006) 5.95
Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med (2004) 5.48
Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol (2007) 4.67
Inactivation of the p53 pathway in retinoblastoma. Nature (2006) 4.57
p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell (2009) 4.30
Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet (2001) 4.23
Distinct thresholds govern Myc's biological output in vivo. Cancer Cell (2008) 4.16
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A (2008) 4.07
The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov (2008) 4.03
p53 suppresses the self-renewal of adult neural stem cells. Development (2006) 3.35
Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol Cell Biol (2002) 3.10
Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J Biol Chem (1999) 2.92
MDMX: from bench to bedside. J Cell Sci (2007) 2.78
Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J Biol Chem (2002) 2.68
Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol (2004) 2.61
Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature (2010) 2.51
Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ (2008) 2.36
Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell (2006) 2.32
Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases. Cancer Cell (2009) 2.28
Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci U S A (2006) 2.20
Temporal dissection of p53 function in vitro and in vivo. Nat Genet (2005) 2.19
An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. EMBO J (2006) 2.11
Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc Natl Acad Sci U S A (2003) 2.07
Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res (2009) 1.87
Mdmx as an essential regulator of p53 activity. Biochem Biophys Res Commun (2005) 1.85
Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem (2010) 1.85
Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci U S A (2006) 1.82
Hdmx stabilizes Mdm2 and p53. J Biol Chem (2000) 1.81
Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Mol Cell Biol (2006) 1.76
A small molecule that disrupts Mdm2-p53 binding activates p53, induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Biol Ther (2008) 1.62
Expansion of hematopoietic stem cell phenotype and activity in Trp53-null mice. Exp Hematol (2003) 1.59
Regulation of the p53 transcriptional response by structurally diverse core promoters. Genes Dev (2009) 1.52
Puma is required for p53-induced depletion of adult stem cells. Nat Cell Biol (2010) 1.41
Distinct roles of Mdm2 and Mdm4 in red cell production. Blood (2006) 1.36
Tissue-specific p19Arf regulation dictates the response to oncogenic K-ras. Proc Natl Acad Sci U S A (2010) 1.28
Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol Cancer Res (2008) 1.27
Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase. FEBS Lett (2009) 1.24
Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity. Cell Stem Cell (2010) 1.21
MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation. J Biol Chem (2001) 1.17
The intestinal epithelium compensates for p53-mediated cell death and guarantees organismal survival. Cell Death Differ (2008) 1.17
Mdm2, but not Mdm4, protects terminally differentiated smooth muscle cells from p53-mediated caspase-3-independent cell death. Cell Death Differ (2006) 1.15
MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. Br J Cancer (2009) 1.06
A small molecule inhibitor of p53 stimulates amplification of hematopoietic stem cells but does not promote tumor development in mice. Cell Cycle (2010) 1.01
Puzzling over MDM4-p53 network. Int J Biochem Cell Biol (2010) 0.88
Tumor-specific induction of apoptosis by a p53-reactivating compound. Exp Cell Res (2008) 0.83
FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell (2007) 12.33
Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest (2007) 9.33
HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell (2008) 8.01
Modeling the therapeutic efficacy of p53 restoration in tumors. Cell (2006) 5.95
Modelling Myc inhibition as a cancer therapy. Nature (2008) 5.81
Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell (2002) 5.29
Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev (2003) 4.71
Distinct thresholds govern Myc's biological output in vivo. Cancer Cell (2008) 4.16
Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. Cell Stem Cell (2010) 4.11
A matter of life and death. Cancer Cell (2002) 4.07
Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med (2007) 3.11
p53--a Jack of all trades but master of none. Nat Rev Cancer (2009) 2.96
The transcription factor EGR1 controls both the proliferation and localization of hematopoietic stem cells. Cell Stem Cell (2008) 2.88
Hematopoietic stem cell quiescence is maintained by compound contributions of the retinoblastoma gene family. Cell Stem Cell (2008) 2.67
FOXO3A directs a protective autophagy program in haematopoietic stem cells. Nature (2013) 2.62
Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature (2010) 2.51
Cell cycle regulation in hematopoietic stem cells. J Cell Biol (2011) 2.48
Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell (2013) 2.46
Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell (2007) 2.42
JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal. Cancer Cell (2009) 2.41
New evidence supporting megakaryocyte-erythrocyte potential of flk2/flt3+ multipotent hematopoietic progenitors. Cell (2006) 2.34
MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice. Cancer Cell (2003) 2.33
Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell (2006) 2.32
Temporal dissection of p53 function in vitro and in vivo. Nat Genet (2005) 2.19
Endogenous Myc maintains the tumor microenvironment. Genes Dev (2011) 2.16
Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. Nat Genet (2006) 2.10
IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell (2011) 2.05
K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells. Blood (2006) 1.93
Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci U S A (2006) 1.89
The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta. Genes Dev (2006) 1.87
Identification of oncogenes collaborating with p27Kip1 loss by insertional mutagenesis and high-throughput insertion site analysis. Proc Natl Acad Sci U S A (2002) 1.85
Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology. Blood (2011) 1.84
MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst (2009) 1.80
The ups and downs of Myc biology. Curr Opin Genet Dev (2009) 1.70
Regulated beta-cell regeneration in the adult mouse pancreas. Diabetes (2007) 1.67
Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol (2009) 1.67
DNA-damage response in tissue-specific and cancer stem cells. Cell Stem Cell (2011) 1.67
Reversible kinetic analysis of Myc targets in vivo provides novel insights into Myc-mediated tumorigenesis. Cancer Res (2006) 1.64
Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev (2013) 1.60
c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. Cancer Res (2004) 1.48
Molecular signatures of quiescent, mobilized and leukemia-initiating hematopoietic stem cells. PLoS One (2010) 1.46
Glucose withdrawal induces oxidative stress followed by apoptosis in glioblastoma cells but not in normal human astrocytes. Mol Cancer Res (2006) 1.42
Mechanisms controlling hematopoietic stem cell functions during normal hematopoiesis and hematological malignancies. Wiley Interdiscip Rev Syst Biol Med (2011) 1.37
Defining the temporal requirements for Myc in the progression and maintenance of skin neoplasia. Oncogene (2004) 1.32
The oncogenic potential of Kaposi's sarcoma-associated herpesvirus cyclin is exposed by p53 loss in vitro and in vivo. Cancer Cell (2002) 1.24
Acute overexpression of Myc in intestinal epithelium recapitulates some but not all the changes elicited by Wnt/beta-catenin pathway activation. Mol Cell Biol (2009) 1.21
A component of the mir-17-92 polycistronic oncomir promotes oncogene-dependent apoptosis. Elife (2013) 1.20
Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons. J Exp Med (2014) 1.18
Chronic versus acute myelogenous leukemia: a question of self-renewal. Cancer Cell (2004) 1.18
Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discov (2013) 1.17
Specific requirement for Bax, not Bak, in Myc-induced apoptosis and tumor suppression in vivo. J Biol Chem (2006) 1.16
Evidence that the Pim1 kinase gene is a direct target of HOXA9. Blood (2007) 1.16
The cell cycle and how it is steered by Kaposi's sarcoma-associated herpesvirus cyclin. J Gen Virol (2004) 1.14
Bid mediates apoptotic synergy between tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and DNA damage. J Biol Chem (2004) 1.11
Bcl-xL gain of function and p19 ARF loss of function cooperate oncogenically with Myc in vivo by distinct mechanisms. Cancer Cell (2006) 1.11
The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy. PLoS One (2011) 1.10
JunB inhibits proliferation and transformation in B-lymphoid cells. Blood (2003) 1.10
Activated Gs signaling in osteoblastic cells alters the hematopoietic stem cell niche in mice. Blood (2012) 1.05
Stem cells assessed. Nat Rev Mol Cell Biol (2012) 1.05
Cancer stem cells are everywhere. Nat Med (2009) 1.03
Insertional mutagenesis in mice deficient for p15Ink4b, p16Ink4a, p21Cip1, and p27Kip1 reveals cancer gene interactions and correlations with tumor phenotypes. Cancer Res (2010) 1.02
The Spy1/RINGO family represents a novel mechanism regulating mammary growth and tumorigenesis. Cancer Res (2008) 1.02
The role of p53 in suppression of KSHV cyclin-induced lymphomagenesis. Cancer Res (2004) 0.98
Malignant mesothelioma cells are rapidly sensitized to TRAIL-induced apoptosis by low-dose anisomycin via Bim. Mol Cancer Ther (2007) 0.96
Finding cancer's weakest link. Oncotarget (2011) 0.96
Outcomes and alternative techniques for device closure of the large secundum atrial septal defect. Catheter Cardiovasc Interv (2004) 0.94
Modeling pharmacological inhibition of mast cell degranulation as a therapy for insulinoma. Neoplasia (2011) 0.92
Dynamic expression of the Robo ligand Slit2 in bone marrow cell populations. Cell Cycle (2012) 0.92
PML-RAR{alpha} and Dnmt3a1 cooperate in vivo to promote acute promyelocytic leukemia. Cancer Res (2010) 0.90
Id2 is dispensable for Myc-induced epidermal neoplasia. Mol Cell Biol (2004) 0.90
Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors. J Clin Invest (2013) 0.90
PTEN deletion and concomitant c-Myc activation do not lead to tumor formation in pancreatic beta cells. J Biol Chem (2008) 0.89
The 5th International Society for Stem Cell Research (ISSCR) Annual Meeting, June 2007. Stem Cells (2007) 0.87
KSHV viral cyclin interferes with T-cell development and induces lymphoma through Cdk6 and Notch activation in vivo. Cell Cycle (2014) 0.87
Prevalence of "silent" pulmonary emboli in adults after the Fontan operation. J Am Coll Cardiol (2003) 0.86
Metabolic makeover for HSCs. Cell Stem Cell (2013) 0.86
All things to all people. Cell (2012) 0.85
Nursing some sense out of Myc. J Biol (2009) 0.85
IFN-alpha wakes up sleeping hematopoietic stem cells. Nat Med (2009) 0.85
Resilient and resourceful: genome maintenance strategies in hematopoietic stem cells. Exp Hematol (2013) 0.85
The transcription factor Srf regulates hematopoietic stem cell adhesion. Blood (2010) 0.84
Absence of caspase-3 protects pancreatic {beta}-cells from c-Myc-induced apoptosis without leading to tumor formation. J Biol Chem (2009) 0.83
Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy. Proc Natl Acad Sci U S A (2013) 0.82
Cancer biology: a game of subversion. Nature (2006) 0.81
From tumor prevention to therapy: empowering p53 to fight back. Drug Resist Updat (2012) 0.81
Linking HSCs to their youth. Nat Cell Biol (2013) 0.80
Wild type p53 transcriptionally represses the SALL2 transcription factor under genotoxic stress. PLoS One (2013) 0.79
Born to survive: autophagy in hematopoietic stem cell maintenance. Cell Cycle (2013) 0.79
Clinical outcomes of patent foramen ovale closure for paradoxical emboli without echocardiographic guidance. Catheter Cardiovasc Interv (2004) 0.79
On the streets of San Francisco: highlights from the ISSCR Annual Meeting 2010. Cell Stem Cell (2010) 0.75
Molecular mechanisms of neuronal cell death: implications for nuclear factors responding to cAMP and phorbol esters. Mol Cell Neurosci (2002) 0.75